晚期肾细胞癌免疫疗法的现状及展望  

Current situation and prospect of immunotherapy for advanced renal cell carcinoma

作　　者：李芳 彭红英 Li Fang;Peng Hongying(Department of Nephrology,Affiliated Hospital of Guizhou Medical University,Guiyang 550004,China;Department of Nephrology,Baiyun Hospital Affiliated to Guizhou Medical University,Guiyang 550014,China)

机构地区：[1]贵州医科大学附属医院肾内科,贵阳550004 [2]贵州医科大学附属白云医院肾内科,贵阳550014

出　　处：《肿瘤研究与临床》2024年第6期477-480,共4页Cancer Research and Clinic

基　　金：贵阳市科技计划(筑科合同[2022]-4-14-5)。

摘　　要：肾细胞癌是泌尿系统常见的恶性肿瘤,其预后较差,晚期患者易发生骨、脑、肺等远处转移。肾细胞癌常见的治疗方式有手术、放化疗、免疫治疗及靶向治疗等。肿瘤微环境在肾细胞癌的发生、病理生理过程及治疗方面有重要作用。肿瘤微环境特征的研究使肾细胞癌治疗取得了巨大进展。目前,免疫治疗与细胞治疗可有效延长肾癌患者的生存期,为晚期肾细胞癌患者提供新的治疗方法。Renal cell carcinoma is a common malignant tumor in urinary system with poor prognosis,and the advanced patients are prone to distant metastases such as bone,brain and lung.Common treatment modalities for renal cell carcinoma include surgery,radiotherapy,immunotherapy and targeted therapy.Tumor microenvironment plays an important role in the occurrence,pathophysiological process and treatment of renal cell carcinoma.The study of tumor microenvironment characteristics has led to significant advances in the treatment of renal cell carcinoma.At present,immunotherapy and cell therapy for renal cancer can effectively prolong the survival of patients and provide new treatment methods for patients with advanced renal cell carcinoma.

关 键 词：癌 肾细胞 肿瘤微环境 免疫检查点抑制剂 分子靶向疗法 细胞疗法 

分 类 号：R737.11[医药卫生—肿瘤]